This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. I was a bit worried last week’s angst-y rant on the bleak state of biotech investing would turn folks off. In fact, it was my most popular…
Continue reading...